Daily News Podcast

Finally, new migraine drugs

Publish date: August 1, 2018

 

Successful phase 3 data for new headache medications (rimegepant, ubrogepant, lasmiditan) are finally raining in after a lengthy drought. Also today, interferon status and family history predict autoimmune connective tissue disease, steroid injection before rotator cuff repair predicts revision, and the CMS resumes risk adjustment payments for 2017. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Bundle pay plan didn’t save money
MDedge Dermatology
Brain damage, slight benefit seen in epinephrine cardiac arrest
MDedge Dermatology
Is fibromyalgia one disorder – or two?
MDedge Dermatology
Is fish oil’s heart benefit a fish tale?
MDedge Dermatology
Blood pressure meds cut cognitive impairment risk
MDedge Dermatology
Antibody cleared amyloid plaques, slowed cognitive decline
MDedge Dermatology
Study explores adolescents’ views on their skin tone, pressure to tan
MDedge Dermatology
Oral drug seen preventing angioedema attacks
MDedge Dermatology
Free skin cancer screening highlights need
MDedge Dermatology
Valsartan cancer risk is low
MDedge Dermatology